Enzyme-Responsive Linkers Enable In Vivo Clearance of Circulating Radioimmunoconjugates. (PubMed, J Nucl Med) - Oct 9, 2026 - "[89Zr]DFO-methotrexate-rituximab was administered to CD1 nude mice carrying subcutaneous Raji xenografts, followed by carboxypeptidase G2 or saline, with subsequent PET imaging and biodistribution studies performed to assess enzyme-mediated changes in imaging contrast. In immunocompromised mice bearing subcutaneous Raji xenografts, administration of [89Zr]DFO-MTX-rituximab followed by carboxypeptidase G2 enhanced the tumor-to-blood imaging signal by greater than 40% compared with saline-treated controls. The use of Food and Drug Administration-approved enzymes to clear radioactivity from circulating radioimmunoconjugates showed significant efficacy in vivo, providing proof of concept for future clinical applications, particularly in hematologic malignancies."
Journal • Preclinical • Hematological Disorders • Hematological Malignancies • Oncology
|
|
Andres Fernandez Del Castillo; Estela Noguera-Ortega; Jonathan M Pham; Lily H Min; Mark A Sellmyer; Stephen J Schuster; Swarbhanu Sarkar
|